CD14 and rheumatoid arthritis: In summary, this study shows that the absolute number of circulating monocytes, and of their CD14+highCD16-, CD14+highCD16+ and CD14+lowCD16+ subsets at three months of anti-TNFα treatment, have a predictive value in terms of the clinical response after six months of anti-TNFα treatment in patients with RA.